Leerink Partnrs Predicts Alumis’ Q2 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – Investment analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Alumis in a research note issued to investors on Sunday, March 23rd. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($1.48) for the quarter. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. Leerink Partnrs also issued estimates for Alumis’ Q3 2025 earnings at ($1.38) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.46) EPS, FY2026 earnings at ($5.19) EPS, FY2027 earnings at ($6.13) EPS, FY2028 earnings at ($3.99) EPS and FY2029 earnings at ($2.04) EPS.

ALMS has been the subject of several other research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Oppenheimer assumed coverage on shares of Alumis in a report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (down previously from $19.00) on shares of Alumis in a research note on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Alumis currently has an average rating of “Buy” and an average target price of $26.00.

Alumis Price Performance

Shares of NASDAQ ALMS opened at $4.00 on Wednesday. The stock has a fifty day simple moving average of $5.55 and a two-hundred day simple moving average of $8.43. Alumis has a 1-year low of $3.18 and a 1-year high of $13.53.

Hedge Funds Weigh In On Alumis

A number of large investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new stake in Alumis during the 3rd quarter worth approximately $27,000. Wells Fargo & Company MN increased its holdings in shares of Alumis by 77.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock worth $69,000 after purchasing an additional 3,823 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alumis in the fourth quarter worth $79,000. MetLife Investment Management LLC bought a new stake in Alumis during the third quarter valued at $89,000. Finally, Marshall Wace LLP purchased a new position in Alumis during the fourth quarter worth about $108,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.